Diabetes Drug Shows Benefit in Parkinson's Disease

(MedPage Today) -- The glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin) led to less progression of motor disability compared with placebo in early Parkinson's disease, the phase II LIXIPARK trial showed. At 12 months, motor...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news